Photochromic compounds
    38.
    发明授权
    Photochromic compounds 有权
    光致变色化合物

    公开(公告)号:US07582749B2

    公开(公告)日:2009-09-01

    申请号:US11925044

    申请日:2007-10-26

    摘要: Various non-limiting embodiments disclosed herein relate generally to photochromic compounds, which may be thermally reversible or non-thermally reversible, and articles made therefrom. Other non-limiting embodiments relate to photochromic-dichroic compounds, which may be thermally reversible or non-thermally reversible, and articles made therefrom. For example, one non-limiting embodiment provides a thermally reversible, photochromic compound adapted to have at least a first state and a second state, wherein the thermally reversible, photochromic compound has an average absorption ratio greater than 2.3 in at least one state as determined according to CELL METHOD. Another non-limiting embodiment provides a photochromic compound comprising: (a) at least one photochromic group chosen from a pyran, an oxazine, and a fulgide; and (b) at least one lengthening agent L attached to the at least one photochromic group and represented by the formula—[S1]c-[Q1 —[S2]d]d′-[Q2 —[S3]e]e′-[Q3 —[S4]f]f′—S5—P, which is described herein.

    摘要翻译: 本文公开的各种非限制性实施方案通常涉及光致变色化合物,其可以是热可逆的或不可逆的,以及由其制成的制品。 其它非限制性实施方案涉及光致变色二色性化合物,其可以是热可逆的或不可逆的,以及由其制备的制品。 例如,一个非限制性实施方案提供了适于具有至少第一状态和第二状态的热可逆的光致变色化合物,其中所述热可逆的光致变色化合物在至少一种状态中的平均吸收比大于2.3,如所确定的 根据细胞方法 另一个非限制性实施方案提供了一种光致变色化合物,其包含:(a)至少一种选自吡喃,恶嗪和吡啶的光致变色基团; 由式 - [S1] c- [Q1- [S2] d] d' - [Q2- [S3] e] e'表示的至少一个延长剂L连接到至少一个光致变色基团上, - [Q3 - [S4] f] f'-S5-P,这里描述。